| Literature DB >> 28074126 |
Ye-Mun Low1, Polly Soo-Xi Yap1, Kartini Abdul Jabar1, Sasheela Ponnampalavanar2, Rina Karunakaran1, Rukumani Velayuthan1, Chun-Wie Chong3, Sazaly Abu Bakar4, Mohd Yasim Md Yusof1, Cindy Shuan-Ju Teh1.
Abstract
BACKGROUND: Carbapenem resistant Enterobacteriaceae is a growing concern worldwide including Malaysia. The emergence of this pathogen is worrying because carbapenem is one of the 'last-line' antibiotics. The main objective of this study was to determine the prevalence of genetic mechanisms and clinical risk factors of carbapenem resistant Klebsiella pneumoniae (K. pneumoniae) in Malaysia.Entities:
Keywords: Carbapenem resistant K. pneumoniae; Enterobacteriaceae; KPC-2; OXA-48; ST101
Year: 2017 PMID: 28074126 PMCID: PMC5219686 DOI: 10.1186/s13756-016-0164-x
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Time-line of events during patient admission period.
Clinical cases of patients from whom carbapenem resistant Klebsiella pneumoniae was isolated
| Isolate | Gender/ Age (years) | Underlying diseases | Isolation site | Length of hospitalization prior to strain isolation (days) | Stay in ICU (days) | Undergone surgical procedure | Use of medical devicesa | Prior antibiotic exposure (90 days prior to strain isolation) | Empiric antibiotic | Targeted antibiotic | Colonization / Infection | In-hospital death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| K/1310-23 | M / 85 | SOT | Blood | 5 | 0 | No | MV, Cath | XM, CI | TZP | CT | Infection | Yes |
| K/1311-36 | M / 72 | HPT | Drainage fluid | 37 | 17 | Yes | MV, Cath | CP, IPb, PM, CLX, TX, CI, TZP, VA, MPb | VA, MP | MP, CT | Infection | Yes |
| K/1308-12 | M / 67 | DM, HPT | Drainage fluid | 21 | 0 | Yes | MV, Cath | CP, MTZ | CI | IP, CT | Infection | No |
| K/1312-3 | M / 60 | DM, HPT | Urine | 110 | 0 | Yes | MV, Cath | P, TZP, IPb | XM, IP | IPd | Colonization | Yes |
| K/1310-33 | F / 63 | DM, HPT, CKD | Blood | 24 | 0 | Unknown | Cath | CFZ, TZ, VA, IPb | CT | CT | Infection | No |
| K/1311-35 | M / 71 | DM, HPT | Sputum | 108 | 5 | Yes | Unknown | VA, CI, MPb | TZ | Nil | Colonization | No |
| K/1312-17 | F / 77 | DM | Urine | 16 | 0 | Yes | Cath | CLX, AMS | CI | Nil | Colonization | No |
| AN9 | F / 62 | HPT | Urine | 16 | 15 | No | MV, Cath | CP, MTZ, AMS | TZP, IPb | IPd | Colonization | No |
| K/1309-5 | F / 48 | DM, HPT | Tissue | 21 | 0 | Yes | MV, Cath | AMS, AMC, TZP, IPb | IPb | Nil | Colonization | No |
| K/1310-24 | F / 69 | DM, HPT | Swab | 155 | 0 | Yes | MV, Cath | VA, MTZ, CT, IPc, CI, XM, TZP | VA, TZP | VA, TZP | Colonization | No |
| KLEB-2013-105 | F / 74 | SOT | Swab | 10 | 0 | Yes | MV, Cath | OTC | AMS | Nil | Colonization | No |
| K/1309-18 | F / 74 | HPT | Tracheal secretion | 10 | 11 | Yes | MV, Cath | CP, MTZ | TZP | Nile | Infection | Yes |
| K/1309-39 | M / 60 | DM, HPT, CKD | Swab | 3 | 0 | Yes | Cath | AMS | AMS | IP, CT | Infection | No |
| K/1304-16 | M / 57 | DM, HPT | Blood | 12 | 0 | Yes | Cath | CI, TX | TZP | IP, CT | Infection | No |
| K/1309-38 | M / 62 | DM, SOT | Urine | 0 | 0 | Yes | MV, Cath | CI, CP, MTZ | TX | IP, CT | Infection | Yes |
| K/1311-26 | F / 57 | DM, HPT, SOT | Blood | 0 | 0 | Unknown | Unknown | AMS, CI | TX | Nil | Colonization | No |
| K/1310-35 | M / 60 | DM, HPT | Tracheal aspirate | 67 | 0 | Yes | MV, Cath | P, TZP | Nil | Nil | Colonization | Yes |
M Male, F Female, SOT Solid organ tumor, DM Diabetes mellitus, HPT Hypertension, CKD Chronic kidney disease, ICU Intensive care unit, MV Mechanical ventilation, Cath catheter, Unknown patient's medical files could not be retrieved, XM Cefuroxime, CI Ciprofloxacin, TZP Piperacillin-tazobactam, CT Colistin, CP Cefoperazone, IP Imipenem, PM Cefepime, CLX Cloxacillin, TX Ceftriaxone, VA Vancomycin, MP Meropenem, MTZ Metronidazole, P Penicillin, CFZ Cefazolin, TZ Ceftazidime, AMS Ampicillin-sulbactam, AMC Amoxicillin-clavulanate, OTC Oxytetracycline
amechanical ventilation and catheter; either urinary catheter, central venous catheter or drainage catheter, bcarbapenem exposure for more than 7 days, ccarbapenem exposure for 3 -7 days, dcarbapenem administered due to other infections, epatient passed away before targeted therapy was initiated
Characteristics of carbapenem resistant Klebsiella pneumoniae associated with in-hospital mortality.
| Characteristics | Survivors ( | Non-survivors ( |
|
|---|---|---|---|
| Age (years) | 64.09 ± 2.57 | 68.83 ± 4.09 | 0.351b |
| Ethnicity | |||
| Malay | 2 | 2 | 0.317c |
| Chinese | 6 | 3 | 0.317c |
| Indian | 3 | 1 | 1.000c |
| Gender | |||
| Male | 4 | 5 | 0.111c |
| Female | 7 | 1 | 0.034c |
| Underlying diseases | |||
| Hypertension | 9 (82%) | 4 (67%) | 0.584 |
| Diabetes mellitus | 9 (82%) | 3 (50%) | 0.280 |
| Solid organ tumor | 2 (18%) | 2 (33%) | 0.584 |
| Chronic kidney disease | 2 (18%) | 0 (0%) | 0.515 |
| Site of isolation | |||
| Blood | 3 (27.3%) | 1 (16.7%) | 0.515 |
| Swabs | 3 (27.3%) | 0 (0%) | 0.515 |
| Urine | 2 (18.2%) | 2 (33.3%) | 0.58 |
| Drainage fluids | 1 (9.1%) | 1 (16.7%) | 1.000 |
| Sputum | 1 (9.1%) | 0 (0%) | 1.000 |
| Tissue | 1 (9.1%) | 0 (0%) | 1.000 |
| Tracheal aspirate | 0 (0%) | 1 (16.7%) | 0.353 |
| Tracheal secretion | 0 (0%) | 1 (16.7%) | 0.353 |
| Length of hospitalization (days) | 35.09 ± 14.88 | 38.17 ± 17.65 | 1.000d |
| Stay in ICU | 2 (18%) | 2 (33%) | 0.584 |
| Undergone surgical procedure | 8 (73%) | 5 (83%) | 1.000 |
| Used ventilation devices | 5 (45%) | 6 (100%) |
|
| Used catheter | 9 (82%) | 6 (100%) | 0.515 |
| Antibiotic prescribed 90 days prior to strain isolation | |||
| Cephalosporins | 6 (55%) | 4 (67%) | 1.000 |
| Penicillins & beta-lactam/beta-lactamase inhibitors | 6 (55%) | 3 (50%) | 1.000 |
| Carbapenems | 4 (36%) | 2 (33%) | 1.000 |
| Colistin | 1 (9%) | 0 | 1.000 |
| Others (ciprofloxacin, vancomycin, metronidazole & oxytetracycline) | 8 (73%) | 4 (67%) | 1.000 |
| Empiric treatment | |||
| Beta-lactam/beta-lactamase inhibitors | 5 (46%) | 2 (33%) | 1.000 |
| Cephalosporins | 2 (18%) | 2 (33%) | 0.584 |
| Carbapenems | 2 (18%) | 2 (33%) | 0.584 |
| Ciprofloxacin | 2 (18%) | 0 | 0.515 |
| Vancomycin | 1 (9%) | 1 (17%) | 1.000 |
| Colistin | 1 (9%) | 0 | 1.000 |
| Targeted therapy | |||
| Carbapenem + Colistin | 3 (27%) | 2 (33%) | 1.000 |
| Colistin | 1 (9%) | 1 (17%) | 1.000 |
| Carbapenem (Meropenem / Imipenem) | 1 (9%) | 1 (17%) | 1.000 |
| Vancomycin & Piperacillin-tazobactam | 1 (9%) | 0 | 1.000 |
| Nila | 5 (46%) | 2 (33%) | 1.000 |
| Colonization / Infection | |||
| Colonization | 7 (63%) | 2 (33%) | 0.162 |
| Infection | 4 (36%) | 4 (67%) | 0.162 |
| Resistance to antibiotics (MIC) | |||
| Imipenem | 10 (91%) | 2 (33%) |
|
| Meropenem | 9 (82%) | 6 (100%) | 0.515 |
| Ertapenem | 9 (82%) | 5 (83%) | 0.232c |
| Carbapenemases | |||
| OXA-48 | 8 (73%) | 4 (67%) | 1.000 |
| KPC-2 | 5 (45%) | 3 (50%) | 1.000 |
| IMP-8 | 2 (18%) | 0 (0%) | 0.515 |
| NMC-A | 0 (0%) | 2 (33%) | 0.110 |
| NDM-1 | 1 (9%) | 0 (0%) | 1.000 |
| AmpC beta-lactamases | |||
| FOX-7 | 11 (100%) | 6 (100%) | NA |
| ESBL | |||
| CTXM-2 | 11 (100%) | 6 (100%) | NA |
| SHV | 11 (100%) | 6 (100%) | NA |
| OXA-1 | 7 (64%) | 2 (33%) | 0.335 |
| CTXM-15 | 6 (55%) | 4 (67%) | 1.000 |
| TEM | 6 (55%) | 3 (50%) | 1.000 |
| OXA-9 | 6 (55%) | 1 (17%) | 0.304c |
Values are expressed as n (%) except where otherwise noted.
atargeted therapy was not administered as strain was colonizer or patient passed away before targeted therapy was initiated
P-values were obtained using Fishers' exact test unless noted otherwise. b P-values obtained using student t test, c P-values obtained using chi-square, d P-values obtained using Mann Whitney U test. The significant P values were highlighted in bold.
MIC for the seventeen carbapenem resistant Klebsiella pneumoniae strains
| Strains | Antibiotics (MIC range in μg/ml) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
aTGC | TC | FX | CT | TZ | TX | PM | IP | MP | ETP | GM | TM | AK | AT | CI | LE |
aCT | |
| K/1310-23 | 2 | >256 | >256 | >256 | >256 | >256 | >256 | 1.5 | 6 | 8 | >256 | >256 | 32 | >256 | >32 | >32 | 1.5 |
| K/1311-36 | 4 | 256 | >256 | 256 | >256 | >256 | >256 | 1.5 | >32 | 6 | 0.094 | 0.19 | 0.5 | >256 | 0.047 | 0.25 | 0.19 |
| K/1308-12 | 1 | >256 | >256 | >256 | >256 | >256 | >256 | >32 | >32 | >32 | >256 | 48 | 24 | >256 | >32 | >32 | 0.38 |
| K/1312-3 | 2 | >256 | 2 | >256 | >256 | >256 | 24 | 1 | 6 | 16 | 0.38 | 1.5 | 256 | 48 | >32 | 8 | 0.125 |
| K/1310-33 | 0.75 | >256 | 128 | >256 | 48 | >256 | >256 | >32 | >32 | >32 | >256 | >256 | 64 | >256 | >32 | >32 | 0.06 |
| K/1311-35 | 0.38 | 6 | 1.5 | 4 | 32 | 8 | 0.38 | 6 | 0.64 | 0.094 | 0.125 | 0.125 | 3 | 24 | 0.125 | 0.5 | 0.19 |
| K/1312-17 | 0.75 | >256 | 128 | 6 | 1 | 4 | 16 | >32 | >32 | >32 | >256 | 128 | 3 | 0.125 | >32 | >32 | 0.125 |
| AN9 | 1.5 | >256 | 48 | 4 | 0.38 | 2 | 1 | >32 | >32 | >32 | >256 | 8 | 3 | 0.19 | >32 | >32 | 0.125 |
| K/1309-5 | 0.38 | >256 | >256 | >256 | 128 | >256 | >256 | 2 | >32 | >32 | >256 | >256 | 24 | >256 | >32 | >32 | 0.19 |
| K/1310-24 | 0.5 | >256 | 2 | 0.75 | 0.19 | 1.5 | 1.5 | 6 | >32 | 6 | 0.19 | 0.19 | 1 | 0.047 | 0.5 | 0.5 | 0.125 |
| KLEB 2013-105 | 0.19 | >256 | 64 | >256 | 128 | >256 | >256 | >32 | >32 | >32 | 96 | >256 | 24 | >256 | >32 | >32 | 0.25 |
| K/1309-18 | 0.75 | >256 | >256 | 6 | 0.5 | 3 | 2 | >32 | >32 | >32 | >256 | 6 | 4 | 0.25 | >32 | >32 | 0.25 |
| K/1309-39 | 0.25 | >256 | >256 | >256 | >256 | >256 | 64 | 12 | >32 | 16 | >256 | >256 | >256 | >256 | >32 | >32 | 0.125 |
| K/1304-16 | 1 | >256 | 3 | 64 | 192 | >256 | 24 | 4 | 0.064 | 0.125 | >256 | >256 | >256 | 192 | >32 | >32 | 0.125 |
| K/1309-38 | 0.19 | >256 | >256 | >256 | 128 | >256 | >256 | 4 | >32 | >32 | >256 | 24 | 12 | >256 | >32 | >32 | 0.38 |
| K/1311-26 | 1 | >256 | 6 | 1 | 0.75 | 1 | 3 | 4 | >32 | 24 | >256 | 64 | 24 | 0.125 | >32 | >32 | 0.38 |
| K/1310-35 | 0.25 | 6 | 3 | 0.75 | 0.094 | 1 | 0.125 | 3 | >32 | 0.75 | 0.125 | 0.25 | 2 | 0.047 | 0.023 | 0.125 | 0.19 |
TGC Tigecycline, TC Tetracycline, FX Cefoxitin, CT Cefotaxime, TZ Ceftazidime, TX Ceftriaxone, PM Cefepime, IP Imipenem, MP Meropenem, ETP Ertapenem, GM Gentamicin, TM Tobramycin, AK Amikacin, AT Aztreonam, CI Ciprofloxacin, LE Levofloxacin, CT Colistin, S Sensitive, I Intermediate, R Resistant, SDD Susceptible-dose dependent
All MIC values were interpreted using CLSI, 2015 guidelines unless noted otherwise. aMIC values were interpreted based on EUCAST breakpoints, 2016
Fig. 2Dendogram of PFGE banding patterns of carbapenem resistant Klebsiella pneumoniae and their sequence type (ST) determined via MLST together with their antibiotic and genotypic profile. IP: imipenem, MP: meropenem, ETP:ertapenem
PCR results of gene specific primers depicting Carbapenemase, AmpC, ESBL, porin protein and Tn4401-like elements in carbapenem resistant Klebsiella pneumoniae strains
| Strain | Sequence Type (ST) | Carbapenemase | AmpC | ESBL | Porin protein | Genetic elements surrounding Tn | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IRL |
| IS | IS | Variable region | IRR | ||||||
| K/1310-23 | 11 | - | FOX-7 | SHV-11, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1311-36 | 495 | KPC-2, NMC-A | FOX-7 | TEM-135, SHV-12, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | + | - | + | - | + | + |
| K/1308-12 | 101 | OXA-48 | FOX-7 | TEM-1, SHV-28, OXA-1, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1312-3 | 13 | OXA-48, KPC-2, NMC-A | FOX-7 | TEM-135, SHV-148, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | + | - | + | + |
| K/1310-33 | 101 | OXA-48, KPC-2 | FOX-7 | TEM-1, SHV-28, OXA-1, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | + | + | + | - |
| K/1311-35 | 1245 | KPC-2 | FOX-7 | SHV-12, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | + | - | - | - | + |
| K/1312-17 | 101 | OXA-48, KPC-2 | FOX-7 | SHV-28, OXA-1, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | + | - | - |
| AN9 | 101 | OXA-48 | FOX-7 | SHV-28, OXA-1, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1309-5 | 101 | OXA-48, KPC-2 | FOX-7 | TEM-1, SHV-28, OXA-1, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | + | + | + | - |
| K/1310-24 | 789 | OXA-48, KPC-2 | FOX-7 | SHV-121, CTXM-2 | OmpK35, OmpK37 | - | - | + | - | + | + |
| KLEB 2013-105 | 101 | OXA-48 | FOX-7 | TEM-1, SHV-28, OXA-1, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1309-18 | 101 | OXA-48 | FOX-7 | SHV-28, OXA-1, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1309-39 | 147 | IMP-8, NDM-1 | FOX-7 | TEM-1, SHV-11, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1309-38 | 101 | OXA-48, KPC-2 | FOX-7 | TEM-1, SHV-28, OXA-1, OXA-9, CTXM-15, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | + | + | + | - |
| K/1311-26 | 101 | OXA-48 | FOX-7 | SHV-28, OXA-1, CTXM-2 | OmpK35, OmpK36, OmpK37 | - | - | - | - | - | - |
| K/1310-35 | 397 | OXA-48 | FOX-7 | SHV-1, CTXM-2 | OmpK35, OmpK36, OmpK37 | + | - | - | - | - | + |
IRL inverted repeat left, tnpA transposase, ISKpn7 insertion sequence 7, ISKpn6 insertion sequence 6, IRR inverted repeat right
Fig. 3Shaded triangles represent inverted repeats (IR) sequences. Empty triangles represent IRs of insertion sequences, ISKpn6 and ISKpn7. The location of the variable region is as labeled. (Adapted from [14] and [22]). a: Schematic representation of intact classical Tn4401. b: Examples of truncated Tn4401 detected in this study. ISKpn7, encodes two consecutive open reading frames (ORF); istA which encodes a 341-amino-acid putative transposase while istB encodes a 259-amino-acid transposition helper protein. TnpA encodes a transposase of 1,009 amino acids while tnpR is a 1,713 bp resolvase gene